Source comparison
BPC-157 for TMJ Research: Protocol Comparison
Bioavailability High. Systemic absorption within 30–60 minutes Moderate. Gastric stability varies by formulation Low. Limited penetration through skin/mucosa Subcutaneous remains the gold standard in published research Dosage Range (Animal Studies) 10–20 mcg/k
This comparison does not assign a generated winner or score.
- Bioavailability
- High. Systemic absorption within 30–60 minutes
- Moderate. Gastric stability varies by formulation
- Low. Limited penetration through skin/mucosa
- Subcutaneous remains the gold standard in published research
- Dosage Range (Animal Studies)
- 10–20 mcg/kg daily
- 100–500 mcg/kg daily (higher dose compensates for lower absorption)
- Not quantified in TMJ studies
- Oral requires 5–10× higher dose to match subcutaneous efficacy
- Administration Frequency
- Daily injection near injury site or systemically
- 2–3 times daily
- Applied directly to jaw joint area (limited research)
- Frequency tied to half-life. Subcutaneous allows once-daily dosing
- Research Support
- Strong. Majority of published studies use this route
- Emerging. Some gastric healing studies show efficacy
- Minimal. Mechanism uncertain for deep joint structures
- Subcutaneous injection has the most robust evidence base for musculoskeletal applications
- Practical Considerations
- Requires sterile technique and reconstitution knowledge
- Easiest for patient compliance
- Non-invasive but unproven for TMJ-specific outcomes
- Route selection depends on research protocol goals and participant comfort